Company / Financials
Coherus Oncology, Inc. Financials
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
-
FY2019
Net Income
$89.8M
FY2019 · +142.9% YoY
Profit Margin
-
FY2019 · net income / revenue
ROE
85.4%
FY2019 · return on equity
Total Assets
$408.9M
FY2019
Total Debt
-
FY2019
Equity
$105.2M
FY2019
ROA
22.0%
FY2019 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations-Net Income HistoryProfit after all expenses and taxes$89.8M+142.9% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$17.1MOperating Income HistoryProfit from core business operations before interest and taxes$107.8M+152.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$137.0M+45.5% YoYR&D Expense HistoryResearch and development spending$94.2M-14.6% YoYInterest Expense HistoryCost of borrowing and debt obligations$17.6M+81.8% YoYIncome Tax HistoryTotal income tax expense$2.9MEPS (Basic) HistoryBasic earnings per share-$4.48EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$4.48-47.4% YoY